AnaptysBio: The Royalty Transition Reaches Its First Quarterly Test Post-Spinoff

AnaptysBio, Inc. (ANAB) is scheduled to report second-quarter 2026 earnings on August 19, 2026, with analysts expecting the biotech to post an EPS of -$0.22 on revenue estimates that remain unavailable. The central question facing investors is whether the company can stabilize its earnings trajectory after a volatile first quarter that saw a massive miss, or if the recent analyst optimism—which has driven consensus estimates sharply higher over the past 90 days—will prove premature.

Part 1: Earnings Preview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody product candidates for autoimmune and inflammatory diseases. The company's pipeline includes treatments targeting conditions such as atopic dermatitis and chronic spontaneous urticaria, with its lead asset rosnilimab in late-stage development.

AnaptysBio is set to report Q2 2026 results on August 19, 2026, with the consensus estimate calling for an EPS of -$0.22 from 3 analysts. The most recently reported quarter (Q1 2026) delivered an actual EPS of -$1.84, representing a significant miss against expectations. Compared to the same quarter last year (Q2 2025), when the company reported -$1.34, the current estimate of -$0.22 would represent an 83.58% improvement year-over-year, suggesting analysts expect a meaningful recovery in profitability.

Three key themes define this earnings story heading into the release:

Pipeline Progress and Regulatory Milestones: Investors will be watching closely for updates on rosnilimab's clinical development program and any progress toward regulatory submissions. The company's ability to advance its lead asset through late-stage trials remains the primary value driver, and any delays or setbacks could significantly impact the stock.

Revenue Trajectory and Commercialization Strategy: With Q1 2026 revenue coming in at $25.56 million—above analyst estimates of $18.86 million—the market will be looking for confirmation that the company can sustain this momentum. The sharp revenue decline expected for the full year (-53.24% growth estimate) creates uncertainty about the company's near-term commercial prospects.

Earnings Volatility and Estimate Reliability: The dramatic swings in recent quarters—from a +149.06% surprise in Q3 2025 to a -475.00% miss in Q1 2026—have made forecasting difficult. Analysts have revised their Q2 estimate upward significantly over the past 90 days (from -$1.04 to -$0.22), but whether this optimism is justified remains the critical question.

Leading analysts remain constructive heading into the release. UBS maintains a Buy rating with a price target of $76, while the broader analyst community shows overwhelming bullish sentiment with 11 Strong Buy ratings out of 12 total recommendations. The consensus price target of $87.09 implies substantial upside from current levels, though the wide range of estimates (from $70 to $140) reflects significant uncertainty about the company's near-term trajectory.

Part 2: Historical Earnings Performance

AnaptysBio has demonstrated extreme volatility in its earnings performance over the past four quarters, making it one of the more unpredictable names in the biotech sector. The company posted three consecutive positive surprises—+10.67% in Q2 2025, +149.06% in Q3 2025, and +77.53% in Q4 2025—before delivering a massive -475.00% miss in Q1 2026 with reported EPS of -$1.84 against an estimate of -$0.32.

The pattern reveals a company in transition, with earnings swinging from deeply negative (-$1.34) to surprisingly positive ($0.52 and $1.58) and back to deeply negative (-$1.84) over just four quarters. The Q3 2025 result was particularly notable, as the company beat by $1.58 per share, turning what was expected to be a loss into a profit. However, the Q1 2026 miss erased any confidence that the company had established a sustainable earnings trajectory.

The magnitude of the Q1 2026 miss—nearly five times worse than expected—suggests either a significant one-time event or fundamental challenges in the business model that analysts failed to anticipate. With the Q2 estimate now calling for -$0.22, representing a dramatic improvement from the -$1.84 reported last quarter, investors face the question of whether analysts have correctly identified a return to normalcy or are once again underestimating the company's challenges.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

AnaptysBio has not specified the timing of its Q2 2026 earnings release, making it difficult to interpret whether Day 0 moves reflect anticipation or immediate reaction.

Historical price behavior around earnings shows average absolute moves of 2.86% on Day 0 and 6.30% on Day +1, with Day +1 ranges averaging 13.16%, indicating significant volatility in the session following results. The most recent earnings release on May 12, 2026, saw the stock decline 3.45% on Day 0 and extend losses to 4.41% by Day +1, consistent with the magnitude of the earnings miss. The March 3, 2026 report produced the strongest positive reaction, with the stock surging 14.61% on Day +1 following a substantial earnings beat. Notably, the stock has shown a tendency for larger moves on Day +1 than Day 0 across most reports, suggesting that investors often need time to digest the results and management commentary before the full reaction materializes. With the stock's average Day +1 range exceeding 13%, options traders and investors should prepare for potentially significant price swings in the session following this release.

Part 3: What Analysts Are Saying

Analyst sentiment on AnaptysBio remains overwhelmingly bullish, with the stock carrying an average recommendation of 4.83 out of 5.0—firmly in Strong Buy territory. The current consensus includes 11 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 12 analysts covering the stock. This represents unchanged sentiment compared to one month ago, indicating that the Q1 earnings miss has not materially altered the Street's long-term conviction in the company's prospects.

The average price target of $87.09 implies 47.6% upside from the current price of $58.98, reflecting substantial optimism about the company's pipeline value and commercial potential. However, the wide range of price targets—from a low of $70.00 to a high of $140.00—reveals significant disagreement among analysts about the appropriate valuation, with the high-end estimate implying more than double the upside of the low-end target. This dispersion suggests that while analysts are uniformly positive on the direction, there is considerable uncertainty about the magnitude and timing of value realization.

Part 4: Technical Picture

The Barchart Technical Opinion for AnaptysBio currently stands at 56% Buy, unchanged from last week but improved from 40% Buy one month ago, indicating a gradual strengthening of technical momentum heading into earnings. The stock is trading at $58.98, positioned above all major moving averages—the 5-day ($58.03), 10-day ($56.99), 20-day ($55.33), 50-day ($57.97), 100-day ($56.20), and 200-day ($44.25)—a bullish configuration that suggests the stock has established a solid technical foundation.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has paused after recent gains, indicating potential consolidation
• Medium-term (100% Buy): Strong buy signal reflects positive intermediate-term trend momentum supporting the current rally
• Long-term (100% Buy): Strong buy signal indicates the longer-term trend remains firmly positive, with the stock well above its 200-day moving average

Trend Characteristics: The combination of Soft strength and Average direction suggests the stock is in a constructive but not overheated uptrend, providing a relatively neutral technical backdrop for the earnings event.

The stock's position above all key moving averages, particularly its 33.3% premium to the 200-day moving average at $44.25, indicates strong long-term momentum that could provide support if earnings disappoint. However, the stock's proximity to its 50-day moving average ($57.97) suggests limited near-term cushion, and a negative earnings surprise could quickly push the stock back toward this key support level. The technical setup is moderately supportive heading into earnings, with the uptrend intact but momentum indicators suggesting the stock may need a positive catalyst to extend gains. Given the average post-earnings move of 6.30% and the stock's recent volatility, traders should be prepared for a test of either the $55 support zone (20-day moving average) on disappointment or a breakout toward the $65-70 range on a positive surprise.